TABLE 2

Results of Cox Proportional Hazards Regression Analyses of OS Probability After Initiation of Abiraterone or Enzalutamide Therapy

UnivariateMultivariate
ParameterHRPHRP
mCRPC patients (n = 71)
 Age at start of treatment1.03 [0.99, 1.06]0.11
 Treatment agent0.48
  Enzalutamide (n = 32)Reference
  Abiraterone (n = 39)1.21 [0.71, 2.08]
 Laboratory parameters at treatment start
  Prostate-specific antigen (log)1.13 [0.95, 1.35]0.17
  Albumin0.55 [0.23, 1.31]0.18
  Alkaline phosphatase (log)1.90 [1.34, 2.70]<0.001Not selected
  Hemoglobin0.80 [0.67, 0.95]0.0130.81 [0.69, 0.96]0.013
  Lactate dehydrogenase1.005 [1.003, 1.008]<0.001Not selected
 18F-FDG PET/CT metrics
  SUVmax (g/mL)1.14 [1.08, 1.21]<0.001Not selected
  Number of 18F-FDG–avid metastases1.08 [1.05, 1.11]<0.001Not selected
  Whole-body MTV (log)1.86 [1.49, 2.33]<0.001Not selected
  Whole-body TLG (log)1.84 [1.51, 2.26]<0.0011.88 [1.53, 2.32]<0.001
mCSPC patients (n = 25)
 Age at start of treatment1.02 [0.9, 1.15]0.76
 Treatment agent0.72
  Enzalutamide (n = 7)Reference
  Abiraterone (n = 18)0.73 [0.13, 3.98]
 Laboratory parameters at treatment start
  Prostate-specific antigen (log)1.07 [0.72, 1.58]0.74
  Albumin1.29 [0.9, 17.2]0.85
  Alkaline phosphatase (log)1.55 [0.59, 4.05]0.37
  Hemoglobin0.66 [0.43, 1.03]0.065
  Lactate dehydrogenase1.00 [0.98, 1.02]0.89
 18F-FDG PET/CT metrics
  SUVmax (g/mL)0.99 [0.90, 1.09]0.80
  Number of 18F-FDG–avid metastases1.03 [0.96, 1.11]0.43
  Whole-body MTV (log)1.21 [0.83, 1.76]0.33
  Whole-body TLG (log)1.18 [0.86, 1.61]0.31
  • “Treatment” indicates treatment with abiraterone plus prednisone, or enzalutamide. “Not selected” indicates not selected during stepwise selection. Data in brackets are 95% CIs.